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Improvement in hyponatremia: insights from the acute and chronic 
therapeutic impact of a vasopressin antagonist in chronic heart 
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Background: Hyponatremia (HYPO) is a known predictor of mortal- 
ity in pts hospitalized for worsening heart failure. However, it is not 
known whether ITYPO is only a marker of disease severity or whether 
improving sodium levels in hyponatremic patients would lead to im- 
proved outcomes. We studied the relationship between changes in serum 
sodium during hospitalization and mortality in hyponatremic patients ad- 
mitted for decompensated heart failure (HI:) in a post-hoc analysis of the 
ACTIV in CHF trial. 
Methods: The ACTIV in CIIF trial randomized 319 pts with systolic dys- 
function hospitalized for worsening HI: to receive placebo or 30, 60, or 90 
mg tolvaptan, a novel vasopressin V2 receptor antagonist. Cox propor- 
tional hazards regression-analysis was used to explore the relationship 
between ITYPO (Na+<136 mEq/L) at baseline and improvements >2 
mEq/L in serum sodium by hospital discharge, and mortality within sixty 
days. 
Results: Mild to moderate HYPO was observed in 69 patients (21.6%), 
with median (IR) levels of 133 (131, 134) mEq/L at baseline. After ad- 
justment for other covariates, HYPO was a highly statistically significant 
predictor of mortality at 60 days post hospital discharge (p<0.005). At 
hospital discharge, 45 out of 69 pts (65.2%) had improvements in serum 
sodium levels >2 mEq/L. These pts had a median (IR) baseline sodium of 
133 (131, 134) mEq/L, as compared with 133 (132, 135) mEq/L in those 
who did not improve by hospital discharge. Pts with a serum sodium 
improvement at discharge had a mortality rate of 15.6% at 60 days post 
discharge, as compared with a 30.4% mortality rate in those showing 
no improvement (p=0.0842, log-rank). After adjustment for other co- 
variates, change in serum sodium within the hospitalization period was 
a statistically significant predictor of mortality at 60 days post hospital 
discharge (p<0.0269). 
Conclusions: Hyponatremia appears to be a modifiable therapeutic tar- 
get and not purely a marker of disease severity. Improvements in serum 
sodium levels during hospitalization were associated with improved mor- 
tality at 60 days. Prospective studies are necessary in this population to 
assess if therapies aimed at increasing serum sodium will result in im- 
proved outcome. 
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Background: The EPHESUS trial demonstrated that patients with acute 
myocardial infarction (AMI) complicated by heart failure (HF) and left 
ventricular systolic dysfunction (LVSD) experienced significant reduc- 
tions in mortality and morbidity with eplerenone treatment started at a 
mean of 7.3 days post-AMI and used with standard therapy during a mean 
16-month follow-up period. Given the adverse impact of hypertension, 
diabetes, and severe LVSD (LVEF_< 30%) on post-AMI outcomes, and 
the increased risk for mortality and morbidity during the first 30 days 
following an AMI in patients with HF and LVSD, the current analysis at 
30 days post-randomization was performed to explore the early onset of 
eplerenone benefit in these high-risk subgroups. 
Methods: In EPHESUS, patients with post-AMI HF and LVSD (ejection 
fraction _<40%) on standard therapies were randomized 3-14 days after 
the index AMI to eplerenone (25 mg titrated to 50 mg QD at 1 month; 
n=3319) or placebo (n=3313). The assessment of the treatment effects at 
30 days post-randomization was performed on the intention-to-treat pa- 
tients in high-risk subgroups using a Cox proportional hazards regression 
model with treatment group as the only factor, stratified by geographic 
region. The estimated 95% confidence intervals were based on the Wald 
test statistic. 
Reductions in risk with eplerenone relat 
End Point History of hyper- Diabetic LVEF < 30% 
tension subgroup subgroup subgroup 
(N=4007) (N=2142) (N=2106) 
Risk Ratio P value Risk Ratio P value Risk Ratio P value 
(95% CI) (95% CI) (95% CI) 
All-cause Mortality 0.68 0.017 0.70 0.066 0.57 0.002 
(0.50, 0.93) (0.47, 1.02) (0.40, 0.82) 
CV Mortality 0.67 0.015 0.68 0.057 0.56 0.002 
(O.48, O.92) (O.45, t.0t) (O.39, O.82) 
CV Mortality/ 0.86 0.138 0.79 0.062 0.71 0.006 
CV Morbidity (0.7t, 1.05) (0.62, t.0t) (0.56, 0.9t) 
Fatal/Nonfatal HF 0.84 0.257 0.61 0.013 0.69 0.059 
Hospitalization (0.62, 1.14) (0.42, 0.90) (0.47, 1.02) 
Sudden Cardiac Death 0.63 0.139 0.57 0.136 0.43 0.01 
(0.35, 1.16) (O.27, 1.19) (O.22, O.82) 
Conclusions: In EPHESUS, eplerenone reduced all-cause mortality by 
32%, 30%, and 43% in the hypertensive, diabetic and LVEF _<30% sub- 
groups, respectively, within 30 days of initiation. Eplerenone also notably 
reduced the other end points, including CV mortality and sudden cardiac 
death, during this period of increased risk. These data demonstrate the 
early benefits of eplerenone in high-risk patients with HF post-AMI and 
suggest the need for early initiation and maintenance of eplerenone treat- 
ment in these patients. 
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Internal thoracic impedance monitoring: a new tool for the early 
diagnosis and treatment of acute heart failure 
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Current therapy of acute heart failure (AHF) is initiated only after the 
appearance of clinical signs that characterized the alveolar stage of pul- 
monary edema. No clinical signs are present during the interstitial stage 
of AHF. 
We utilized a monitor based on the novel principal of Internal Tho- 
racic Impedance (ITI) measurement that allows recognition of small fluid 
changes in the lung.Device was applied in AMI patients for the diagnosis 
of the interstitial stage of AHF and to examine whether early initiation 
of treatment can prevent the alveolar stage of AHF. Patients without evi- 
dence of AHF on admission were monitored for 72 hours. ITI, respiratory 
rate, heart rate, lung rales and blood saturation were measured every 30 
minutes. 
Study included 399 patients (mean age 63.14-12.8) with AMI. Of 
these,315 remained without AHF (group 1),63 patients developed AHF 
throughout monitoring (group 2), and 21 received early treatment(group 
3).Lung rales was the first clinical sign to appear of all variables. ITI 
decrease in group 1 was 4.54-3.3% (NS) from initial value (range, 0- 
11.5%). All group 2 patients developed mild AHF, 80% progressed to 
